Disease control and management

Globally, the main contributors to morbidity and mortality are chronic conditions, including cardiovascular disease and diabetes. Chronic disease is costly and partially avoidable, with around 60% of deaths and nearly 50% of the global disease burden attributable to these conditions. By 2020, chronic illnesses will likely be the leading cause of disability worldwide. Existing healthcare systems that focus on acute episodic health conditions, both national and international, cannot address the worldwide transition to chronic illness; nor are they appropriate for the ongoing care and management of those already dealing with chronic diseases. As such, chronic disease management requires integrated approaches that incorporate interventions targeted at both individuals and populations, and emphasise the shared risk factors of different conditions. International and Australian strategic planning documents articulate similar elements to manage chronic disease, including the need for aligning sectoral policies for health, forming partnerships, and engaging communities in decision-making. Infectious diseases are also a common and significant contributor to ill health throughout the world. In many countries, this impact has been minimised by the combined efforts of preventative health measures and improved treatment methods. However, in low-income countries, infectious diseases remain the dominant cause of death and disability. The World Health Organization (WHO) estimates that infectious diseases (including respiratory infections) still account for around 23% (or around 14 million) of all deaths each year, and result in over 4.6 billion episodes of diarrhoeal disease and 243 million cases of malaria each year (Lozano et al. 2012, WHO 2009). In addition to the high level of mortality, infectious diseases disable many hundreds of millions of people each year, mainly in developing countries, with the global burden of disease from infectious diseases estimated to be around 300 million DALYs (disability-adjusted life years) (WHO 2012). The aim of this chapter is to outline the impact that infectious diseases and chronic diseases have on the health of the community, describe the public health strategies used to reduce the burden of those diseases, and discuss the historic and emerging disease risks to public health. This chapter examines the comprehensive approaches implemented to prevent both chronic and infectious diseases, and to manage and care for communities with these conditions.

Economía de la salud, modalidades de evaluación económica

La salud es un aspecto muy importante en la vida de cualquier persona, de forma que, al ocurrir cualquier contingencia que merma el estado de salud de un individuo o grupo de personas, se debe valorar estrictamente y en detalle las distintas alternativas destinadas a combatir la enfermedad. Esto se debe a que, la calidad de vida de los pacientes variará dependiendo de la alternativa elegida. La calidad de vida relacionada con la salud (CVRS) se entiende como el valor asignado a la duración de la vida, modificado por la oportunidad social, la percepción, el estado funcional y la disminución provocadas por una enfermedad, accidente, tratamiento o política (Sacristán et al, 1995). Para determinar el valor numérico asignado a la CVRS, ante una intervención, debemos beber de la teoría económica aplicada a las evaluaciones sanitarias para nuevas intervenciones. Entre los métodos de evaluación económica sanitaria, el método coste-utilidad emplea como utilidad, los años de vida ajustado por calidad (AVAC), que consiste, por un lado, tener en cuenta la calidad de vida ante una intervención médica, y por otro lado, los años estimados a vivir tras la intervención. Para determinar la calidad de vida, se emplea técnicas como el Juego Estándar, la Equivalencia Temporal y la Escala de Categoría. Estas técnicas nos proporcionan un valor numérico entre 0 y 1, siendo 0 el peor estado y 1 el estado perfecto de salud. Al entrevistar a un paciente a cerca de la utilidad en términos de salud, puede haber riesgo o incertidumbre en la pregunta planteada. En tal caso, se aplica el Juego Estándar con el fin de determinar el valor numérico de la utilidad o calidad de vida del paciente ante un tratamiento dado. Para obtener este valor, al paciente se le plantean dos escenarios: en primer lugar, un estado de salud con probabilidad de morir y de sobrevivir, y en segundo lugar, un estado de certeza. La utilidad se determina modificando la probabilidad de morir hasta llegar a la probabilidad que muestra la indiferencia del individuo entre el estado de riesgo y el estado de certeza. De forma similar, tenemos la equivalencia temporal, cuya aplicación resulta más fácil que el juego estándar ya que valora en un eje de ordenadas y abscisas, el valor de la salud y el tiempo a cumplir en esa situación ante un tratamiento sanitario, de forma que, se llega al valor correspondiente a la calidad de vida variando el tiempo hasta que el individuo se muestre indiferente entre las dos alternativas. En último lugar, si lo que se espera del paciente es una lista de estados de salud preferidos ante un tratamiento, empleamos la Escala de Categoría, que consiste en una línea horizontal de 10 centímetros con puntuaciones desde 0 a 100. La persona entrevistada coloca la lista de estados de salud según el orden de preferencia en la escala que después es normalizado a un intervalo entre 0 y 1. Los años de vida ajustado por calidad se obtienen multiplicando el valor de la calidad de vida por los años de vida estimados que vivirá el paciente. Sin embargo, ninguno de estas metodologías mencionadas consideran el factor edad, siendo necesario la inclusión de esta variable. Además, los pacientes pueden responder de manera subjetiva, situación en la que se requiere la opinión de un experto que determine el nivel de discapacidad del aquejado. De esta forma, se introduce el concepto de años de vida ajustado por discapacidad (AVAD) tal que el parámetro de utilidad de los AVAC será el complementario del parámetro de discapacidad de los AVAD Q^i=1-D^i. A pesar de que este último incorpora parámetros de ponderación de edad que no se contemplan en los AVAC. Además, bajo la suposición Q=1-D, podemos determinar la calidad de vida del individuo antes del tratamiento. Una vez obtenido los AVAC ganados, procedemos a la valoración monetaria de éstos. Para ello, partimos de la suposición de que la intervención sanitaria permite al individuo volver a realizar las labores que venía realizando. De modo que valoramos los salarios probables con una temporalidad igual a los AVAC ganados, teniendo en cuenta la limitación que supone la aplicación de este enfoque. Finalmente, analizamos los beneficios derivados del tratamiento (masa salarial probable) si empleamos la tabla GRF-95 (población femenina) y GRM-95 (población masculina).

Prices need no preferences: social trends determine decisions in experimental markets for pain relief.

OBJECTIVE: A standard view in health economics is that, although there is no market that determines the "prices" for health states, people can nonetheless associate health states with monetary values (or other scales, such as quality adjusted life year [QALYs] and disability adjusted life year [DALYs]). Such valuations can be used to shape health policy, and a major research challenge is to elicit such values from people; creating experimental "markets" for health states is a theoretically attractive way to address this. We explore the possibility that this framework may be fundamentally flawed-because there may not be any stable values to be revealed. Instead, perhaps people construct ad hoc values, influenced by contextual factors, such as the observed decisions of others. METHOD: The participants bid to buy relief from equally painful electrical shocks to the leg and arm in an experimental health market based on an interactive second-price auction. Thirty subjects were randomly assigned to two experimental conditions where the bids by "others" were manipulated to follow increasing or decreasing price trends for one, but not the other, pain. After the auction, a preference test asked the participants to choose which pain they prefer to experience for a longer duration. RESULTS: Players remained indifferent between the two pain-types throughout the auction. However, their bids were differentially attracted toward what others bid for each pain, with overbidding during decreasing prices and underbidding during increasing prices. CONCLUSION: Health preferences are dissociated from market prices, which are strongly referenced to others' choices. This suggests that the price of health care in a free-market has the capacity to become critically detached from people's underlying preferences.

mHealth and global mental health: still waiting for the mH2 wedding?

BACKGROUND: Two phenomena have become increasingly visible over the past decade: the significant global burden of disease arising from mental illness and the rapid acceleration of mobile phone usage in poorer countries. Mental ill-health accounts for a significant proportion of global disability-adjusted life years (DALYs) and years lived with disability (YLDs), especially in poorer countries where a number of factors combine to exacerbate issues of undertreatment. Yet poorer countries have also witnessed significant investments in, and dramatic expansions of, mobile coverage and usage over the past decade. DEBATE: The conjunction of high levels of mental illness and high levels of mobile phone usage in poorer countries highlights the potential for "mH(2)" interventions--i.e. mHealth (mobile technology-based) mental health interventions--to tackle global mental health challenges. However, global mental health movements and initiatives have yet to engage fully with this potential, partly because of scepticism towards technological solutions in general and partly because existing mH(2) projects in mental health have often taken place in a fragmented, narrowly-focused, and small-scale manner. We argue for a deeper and more sustained engagement with mobile phone technology in the global mental health context, and outline the possible shape of an integrated mH(2) platform for the diagnosis, treatment, and monitoring of mental health. SUMMARY: Existing and developing mH(2) technologies represent an underutilised resource in global mental health. If development, evaluation, and implementation challenges are overcome, an integrated mH2 platform would make significant contributions to mental healthcare in multiple settings and contexts.

Burden of Cancer in a Large Consortium of Prospective Cohorts in Europe

BACKGROUND: Disability-adjusted life-years (DALYs) are an indicator of mortality, morbidity, and disability. We calculated DALYs for cancer in middle-aged and older adults participating in the Consortium on Health and Ageing Network of Cohorts in Europe and the United States (CHANCES) consortium.

METHODS: A total of 90 199 participants from five European cohorts with 10 455 incident cancers and 4399 deaths were included in this study. DALYs were calculated as the sum of the years of life lost because of premature mortality (YLLs) and the years lost because of disability (YLDs). Population-attributable fractions (PAFs) were also estimated for five cancer risk factors, ie, smoking, adiposity, physical inactivity, alcohol intake, and type II diabetes.

RESULTS: After a median follow-up of 12 years, the total number of DALYs lost from cancer was 34 474 (382 per 1000 individuals) with a similar distribution by sex. Lung cancer was responsible for the largest number of lost DALYs (22.9%), followed by colorectal (15.3%), prostate (10.2%), and breast cancer (8.7%). Mortality (81.6% of DALYs) predominated over disability. Ever cigarette smoking was the risk factor responsible for the greatest total cancer burden (24.0%, 95% confidence interval [CI] = 22.2% to 26.0%), followed by physical inactivity (4.9%, 95% CI = 0.8% to 8.1%) and adiposity (1.8%, 95% CI = 0.2% to 2.8%).

CONCLUSIONS: DALYs lost from cancer were substantial in this large European sample of middle-aged and older adults. Even if the burden of disease because of cancer is predominantly caused by mortality, some cancers have sizeable consequences for disability. Smoking remained the predominant risk factor for total cancer burden.

Medición de la carga de enfermedad en una Entidad Promotora de Salud de Colombia año 2008

Introducción: los AVAD (años de vida ajustados a discapacidad) son la unidad de medida de la carga de enfermedad, permiten estimar las pérdidas de salud para una población con respecto a las consecuencias mortales y no mortales de las enfermedades. Metodología: se siguió la metodología del estudio de Carga Global de Enfermedad 2001. Para cálcular los AVAD´s se generan primero sus insumos: Años Vividos con Discapacidad y Años de Vida perdidos por muerte Prematura para lo cual se realizó una tabla de vida actual para la mortalidad general y se tomó la prevalencia de las enfermedades para la morbilidad. Resultados: la tasa de AVAD´s estimada en este estudio fue de 246 AVAD´s por mil personas, correspondientes a 366678 AVAD´s totales, concentrados en su mayoría en las enfermedades del grupo II con un total de 228 AVAD´s por mil habitantes, seguido del grupo I con 17,3 AVAD´s por mil habitantes; y con la menor participación, el grupo III con 0,6 AVAD´s. Los AVAD´s dependientes de la mortalidad fueron 2,4 por mil personas y 244 por discapacidad. La Enfermedad Pulmonar Obstructiva Crónica en ambos géneros ocupa el primer lugar como enfermedad generadora de AVAD´s. Discusión: el 17% de AVAD´s en este estudio pertenecen al grupo I, cifra que se aproxima a la obtenida en nuestro país. El menor peso porcentual se encuentra en el número de AVAD´s del grupo III tanto para Colombia como para la E.P.S. Las limitaciones del estudio se relacionan con la calidad de los datos de los registros de mortalidad.

Comparación farmacoeconómica (costo – utilidad / beneficio / efectividad) del Rituximab, con el tratamiento convencional para pacientes con Linfoma No Hodgkins

El Linfoma no Hodgkin es un cáncer maligno que tiene baja incidencia a nivel nacional pero altos costos en la atención catalogándose por su manejo como enfermedad de alto costo. El tratamiento de acuerdo a fase de tratamiento, clasificación histológica y respuesta a tratamiento se consideran las alternativas de tratamiento determinadas en guías clínicas en este trabajo se revisará el tratamiento con quimioterapia (CHOP) y el tratamiento con Rituximab + CHOP Objetivo: Evaluar comparativamente el tratamiento con quimioterapia y el Rituximab en cuanto a costo beneficio / utilidad /efectividad y el efecto de ambas terapias sobre la calidad de vida y carga de enfermedad, desde la perspectiva del marco normativo vigente y la aplicación del mismo en una EPS Resultados: en los análisis de costo beneficio, utilidad y efectividad, se evidenció que los costos del tratamiento del Rituximab superan los de quimioterapia, pero al comparar los resultados obtenidos mediante AVISA, y QALY, confirmaron los resultados evidenciados en literatura, siendo estas las variables más sensibles para determinación de protocolos de manejo de Linfoma No Hodgkin. Conclusiones: aunque el Rituximab es una buena opción terapéutica para el Linfoma No Hodgkin, los costos que se ocasionan por este medicamento sobrepasan la compensación recibida por estos usuarios, es necesario que las políticas públicas relacionen este tipo de análisis para adecuar los ingresos a los egresos y permitir el equilibrio económico de la atención, no permitir que por cuestiones de economía empresarial se tomen alternativas equivocas que pueden ir el menos cabo de la salud de los usuarios.

Prevalencia de síntomas osteomúsculares en centro médico de medicina prepagada, durante el año 2013.Bogotá.

Objetivo: determinar la prevalencia de síntomas osteomusculares, en los trabajadores administrativos y asistenciales en un centro médico de medicina prepagada en Bogotá, durante el año 2013. Método: Se trata de un estudio descriptivo, de corte transversal, realizado en trabajadores que desarrollan actividades asistenciales y administrativas en un centro médico de medicina prepagada en Bogotá, durante el año 2013, dentro del cual se aplicó a 93 trabajadores el Cuestionario Estandarizado Nórdico en su versión validada al español para la detección y análisis de los síntomas músculo-esqueléticos. Resultado: Se encontró una alta prevalencia en síntomas localizados en región lumbar (50,5%), seguido de síntomas en cuello (46,2%) y manos (44,2%). La población estudiada en su mayoría fue del género femenino (84,9%). En cuanto a la distribución por edad gran parte se encuentra entre el rango de 30 a 49 años (67,7%), así mismo, de acuerdo al área de trabajo la mayoría son administrativos (36,6%). Con respecto a las asociaciones, encontramos mayor frecuencia de síntomas lumbares en el género femenino que en el masculino y los síntomas en manos se presentan comúnmente en el personal asistencial. Conclusión: Durante el estudio se demostró que los síntomas osteomusculares son habituales en la población estudiada, además de su relación con otros estudios, los cuales ponen de manifiesto cómo los factores de riesgo ocupacionales son condiciones determinantes para la aparición de estos síntomas, de lo cual se puede inferir la necesidad de implementar programas a futuro para disminuir la prevalencia y severidad de estas lesiones.

Prevalencia de síntomas musculo-esqueléticos en trabajadores de una institución de educación superior en el departamento de Arauca, Colombia, 2015

Introducción Los desórdenes musculo esqueléticos representan uno de los problemas de salud ocupacional más comunes de trabajadores, lo cual genera ausentismo laboral y aumento en los costos de enfermedades laborales. Objetivo Estimar la prevalencia de síntomas osteomusculares y su relación con factores de riesgo ocupacional, en personal docente y administrativo de una institución de educación superior en el Departamento de Arauca para el año 2015. Métodos Estudio analítico de corte transversal en una muestra de 116 trabajadores. Se utilizaron dos instrumentos: “La Encuesta Nacional de Condiciones de Trabajo” del Instituto Nacional de Seguridad e Higiene en el Trabajo de España (INSHT) y el “Cuestionario Ergopar”, validados al Español. Se obtuvo previa autorización del Comité de ética de la Universidad del Rosario. El análisis estadístico se realizó con el IBM SPSS Statistics versión 20.0. Resultados: Los síntomas osteomusculares con mayor prevalencia fueron en cuello (86,2%), espalda lumbar (61,2%), manos muñecas (59,5%) y pies (52,6%); no se observaron diferencias estadísticamente significantes entre administrativos e instructores. En el lugar de trabajo los factores de riesgo con mayor prevalencia fueron exposición a temperaturas extremas (48,3%), aberturas y huecos desprotegidos, escaleras, plataformas, desniveles (44%) significativamente mayor en instructores (52,6%) que en personal administrativo (27,5%) (p= 0,010). Conclusiones: Los síntomas osteomusculares más prevalentes fueron aquellos propios de la actividad docente: cuello, espalda lumbar, manos muñecas y pies. El personal de la institución en especial los docentes está expuesto a factores de riesgo físico, químico y ergonómico. Las condiciones de trabajo son adecuadas. No se encontró asociación estadística entre exposición a factores de riesgo en el puesto de trabajo y prevalencia de síntomas osteomusculares. Se debe establecer acciones dirigidas a evitar lesiones musculo esqueléticas en la población.

Economic Impact of a Rotavirus Vaccine in Brazil

The study was done to evaluate the cost-effectiveness of a national rotavirus vaccination programme in Brazilian children from the healthcare system perspective. A hypothetical annual birth-cohort was followed for a five-year period. Published and national administrative data were incorporated into a model to quantify the consequences of vaccination versus no vaccination. Main outcome measures included the reduction in disease burden, lives saved, and disability-adjusted life-years (DALYs) averted. A rotavirus vaccination programme in Brazil would prevent an estimated 1,804 deaths associated with gastroenteritis due to rotavirus, 91,127 hospitalizations, and 550,198 outpatient visits. Vaccination is likely to reduce 76% of the overall healthcare burden of rotavirus-associated gastroenteritis in Brazil. At a vaccine price of US$ 7-8 per dose, the cost-effectiveness ratio would be US$ 643 per DALY averted. Rotavirus vaccination can reduce the burden of gastroenteritis due to rotavirus at a reasonable cost-effectiveness ratio.

Cost-effectiveness of introducing the 10-valent pneumococcal conjugate vaccine into the universal immunisation of infants in Brazil

Background Cost-effectiveness studies have been increasingly part of decision processes for incorporating new vaccines into the Brazilian National Immunisation Program. This study aimed to evaluate the cost-effectiveness of 10-valent pneumococcal conjugate vaccine (PCV10) in the universal childhood immunisation programme in Brazil. Methods A decision-tree analytical model based on the ProVac Initiative pneumococcus model was used, following 25 successive cohorts from birth until 5 years of age. Two strategies were compared: (1) status quo and (2) universal childhood immunisation programme with PCV10. Epidemiological and cost estimates for pneumococcal disease were based on National Health Information Systems and literature. A 'top-down' costing approach was employed. Costs are reported in 2004 Brazilian reals. Costs and benefits were discounted at 3%. Results 25 years after implementing the PCV10 immunisation programme, 10 226 deaths, 360 657 disability-adjusted life years (DALYs), 433 808 hospitalisations and 5 117 109 outpatient visits would be avoided. The cost of the immunisation programme would be R$10 674 478 765, and the expected savings on direct medical costs and family costs would be R$1 036 958 639 and R$209 919 404, respectively. This resulted in an incremental cost-effectiveness ratio of R$778 145/death avoided and R$22 066/DALY avoided from the society perspective. Conclusion The PCV10 universal infant immunisation programme is a cost-effective intervention (1-3 GDP per capita/DALY avoided). Owing to the uncertain burden of disease data, as well as unclear long-term vaccine effects, surveillance systems to monitor the long-term effects of this programme will be essential.

Charles P. Daly's Gendered Geography, 1860-1890

The American Geographical Society (AGS) serves as a case study for considering the nature of “gendered geography” in the nineteenth-century United States. This article links the ideals and programmatic interests of the society—which were fundamentally commercial in nature—with the personal subjectivity of its chief protagonist, Charles P. Daly, AGS president from 1864 until his death in 1899. Daly is presented as an “armchair explorer” who shifted the focus of the society away from statistical representations of the world toward the action packed narrative descriptions of the world supplied by embodied explorers in the field. The gender dynamics associated with the center versus the field provide a useful way to contrast both sides of Daly’s persona—as a scholar performing detached, careful study yet someone who also derived a great deal of personal authority by staging popular and dramatic spectacles in New York City, speechifying and presenting himself on stage at geographical society meetings with returning heroic explorers. Daly not only served as New York’ smost influential access point to the Arctic at the time, he also served as an important node in the reproduction of masculine culture in promotion of a particularly masculinist commercial geography. Key Words: American Geographical Society, Charles Patrick Daly, gender and geography, history of geography, masculinity.

Unpopular Archives

This article explores the “unpopular” archived life of Charles P. Daly, thirty-five-year president (1864–1899) of the New York–based American Geographical Society. This one-time highly prominent judge and civic leader popularized geography among professionals and the public alike. Daly’s popular geography, along with his subsequent containment within the archives, suggests explanations for his dismissal among geographical audiences of today. It is a useful and necessary exercise to trace the neglect of Daly within histories of geography and recapture him for today’s audiences, not only because of his influence on post–Civil War American geography but also because his story can shed light on how “disciplinary remembering” functions in geography.

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

Cardiovascular disease (CVD) due to atherosclerosis of the arterial vessel wall and to thrombosis is the foremost cause of premature mortality and of disability-adjusted life years (DALYs) in Europe, and is also increasingly common in developing countries.1 In the European Union, the economic cost of CVD represents annually E192 billion1 in direct and indirect healthcare costs. The main clinical entities are coronary artery disease (CAD), ischaemic stroke, and peripheral arterial disease (PAD). The causes of these CVDs are multifactorial. Some of these factors relate to lifestyles, such as tobacco smoking, lack of physical activity, and dietary habits, and are thus modifiable. Other risk factors are also modifiable, such as elevated blood pressure, type 2 diabetes, and dyslipidaemias, or non-modifiable, such as age and male gender. These guidelines deal with the management of dyslipidaemias as an essential and integral part of CVD prevention. Prevention and treatment of dyslipidaemias should always be considered within the broader framework of CVD prevention, which is addressed in guidelines of the Joint European Societies’ Task forces on CVD prevention in clinical practice.2 – 5 The latest version of these guidelines was published in 20075; an update will become available in 2012. These Joint ESC/European Atherosclerosis Society (EAS) guidelines on the management of dyslipidaemias are complementary to the guidelines on CVD prevention in clinical practice and address not only physicians [e.g. general practitioners (GPs) and cardiologists] interested in CVD prevention, but also specialists from lipid clinics or metabolic units who are dealing with dyslipidaemias that are more difficult to classify and treat.

Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models

Background: WHO's 2013 revisions to its Consolidated Guidelines on antiretroviral drugs recommend routine viral load monitoring, rather than clinical or immunological monitoring, as the preferred monitoring approach on the basis of clinical evidence. However, HIV programmes in resource-limited settings require guidance on the most cost-effective use of resources in view of other competing priorities such as expansion of antiretroviral therapy coverage. We assessed the cost-effectiveness of alternative patient monitoring strategies. Methods: We evaluated a range of monitoring strategies, including clinical, CD4 cell count, and viral load monitoring, alone and together, at different frequencies and with different criteria for switching to second-line therapies. We used three independently constructed and validated models simultaneously. We estimated costs on the basis of resource use projected in the models and associated unit costs; we quantified impact as disability-adjusted life years (DALYs) averted. We compared alternatives using incremental cost-effectiveness analysis. Findings: All models show that clinical monitoring delivers significant benefit compared with a hypothetical baseline scenario with no monitoring or switching. Regular CD4 cell count monitoring confers a benefit over clinical monitoring alone, at an incremental cost that makes it affordable in more settings than viral load monitoring, which is currently more expensive. Viral load monitoring without CD4 cell count every 6—12 months provides the greatest reductions in morbidity and mortality, but incurs a high cost per DALY averted, resulting in lost opportunities to generate health gains if implemented instead of increasing antiretroviral therapy coverage or expanding antiretroviral therapy eligibility. Interpretation: The priority for HIV programmes should be to expand antiretroviral therapy coverage, firstly at CD4 cell count lower than 350 cells per μL, and then at a CD4 cell count lower than 500 cells per μL, using lower-cost clinical or CD4 monitoring. At current costs, viral load monitoring should be considered only after high antiretroviral therapy coverage has been achieved. Point-of-care technologies and other factors reducing costs might make viral load monitoring more affordable in future. Funding: Bill & Melinda Gates Foundation, WHO.